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A 15-year-old boy developed contact dermatitis after a
foot injury treated with diclofenac. Two years later he
ingested diclofenac p.o. for pain relief after exercise. The
following day he showed a generalized eczema, fading
away during the next two weeks. Subsequently paraceta-
mol was well tolerated but had no sufficient analgetic
effect. Patch testing was performed with different non-
steroidal drugs (ibuprofen, acetylic acid, indometacin, cele-
coxib, and piroxicam) in concentrations of 1% , 5 % and 10
% diluted in petrolatum, confirming contact sensitivity to
diclofenac. Piroxicam showed a positive patch test reac-
tion, although the patient denied any former contact to
the substance. Cross-reactivity can be excluded as both
analgetics belong to chemically different groups of
NSAID. Ibuprofen was orally exposed and well-tolerated.
Recent data have demonstrated that delayed hypersensitiv-
ity reactions due to drug-specific T-cells may be subclassi-
fied by their cytokine and chemokine releasing profile
evolving into different clinical manifestations. Activation
of monocytes (type IVa), eosinophils (type IVb) and neu-
trophils (type IVd) may dominate the reaction, cyctotoxic
CD4(+) or CD8(+) T-cells seem to play a part in all
delayed-type reactions. As contact sensitivity to piroxicam
is rarely reported, possible mechanisms are discussed.
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